Recent advances in targeted drug delivery systems for multiple myeloma

Despite significant therapeutic advances, multiple myeloma (MM) remains a challenging, incurable, hematological malignancy. The efficacy of traditional chemotherapy and currently available anti-MM agents is in part limited by their adverse effects, which restrict their therapeutic potential. Nanotherapeutics is an emerging field of cancer therapy that can overcome the biological and chemical barriers of existing anticancer drugs. This review presents an overview of recent advancements in nanoparticle- and immunotherapy-based drug delivery systems for MM treatment. It further delves into the targeting strategies, mechanism of controlled drug release, and challenges associated with the development of drug delivery systems for the treatment of MM. [Display omitted] •Current MM treatments often cause off-target effects, highlighting the need for targeted drug delivery systems.•This review highlights the challenges associated with the currently available MM therapies.•This review summarizes the novel targeted delivery systems (prodrugs and nanoformulations) that have been explored.•This review highlights clinical and pre-clinical studies on antibody-based and nanoparticle-based immunotherapies for MM.